Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AVROBIO Inc | AVRO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.19 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.19 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.57 - 1.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.19 | USD |
AVROBIO Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 53.38M | 44.86M | - | 0 | 12.4M | 0.28 | 4.31 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AVROBIO News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVRO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.23 | 1.26 | 1.18 | 1.20 | 107,293 | -0.04 | -3.25% |
| 1 Month | 1.26 | 1.31 | 1.18 | 1.25 | 120,957 | -0.07 | -5.56% |
| 3 Months | 1.25 | 1.36 | 1.15 | 1.28 | 213,753 | -0.06 | -4.80% |
| 6 Months | 1.54 | 1.61 | 1.01 | 1.32 | 280,662 | -0.35 | -22.73% |
| 1 Year | 0.90 | 1.70 | 0.57 | 1.29 | 977,857 | 0.29 | 32.22% |
| 3 Years | 11.33 | 12.005 | 0.56 | 2.05 | 688,528 | -10.14 | -89.50% |
| 5 Years | 19.98 | 29.32 | 0.56 | 5.51 | 541,665 | -18.79 | -94.04% |
AVROBIO Description
| Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease. |
